07-Apr-2005 16:04



JC03 Rec'd PCT/PTO 07 APR 2005

703-905-2500

T-559 P.001 RECEIVED

CENTRAL FAX CENTER

Attorney's Docket 037003-0313914 Client Reference: 2001-30-0178QUS

APR 0 7 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Confirmation No:

KANDASAMY HARIHARAN ET AL.

Group Art Unit: Unassigned

Filed: December 6, 2004

Application No.: Unassigned

Examiner: Unassigned

Title: GENES OVEREXPRESSED BY CANCER AND THEIR USE IN DEVELOPING

NOVEL THERAPEUTICS

Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATION OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. §1.8

I hereby certify that the following papers (a total of 20 pages including this cover sheet) are being facsimile transmitted to the Patent and Trademark Office at (703) 872-9306 on the date shown below:

> (1) Petition Under 37 C.F.R. 1.181(a) to Accord U.S. Application Number and Filing Date (2 pages)

> (2) Copy of Request for National Stage Entry Filed 12/06/04. including accompanying documents and USPTO date-stamped receipt (17 pages)

> > PILLSBURY WINTHROP SHAW PITTMAN LLP

APR I I 2005
TOF OF PETMONS THOMAS A. CAWLEY, JR., PH.D. Reg. No. 40944

Date: April 7, 2005 P.O. Box 10500 McLean, VA 22102

Telephone: (703) 905-2000 Facsimile: (703) 905-2500

(Certification of Facsimile Transmission-page 1)

JC03 Rec'd PCT/PTO 07 APR 2005

07-Apr-2005 16:05

From-PILLSBURY WINTHROP

703-905-2500

T-559 P.006/020 F-440

U.S. Patent All red and Control of DE ARTMENT OF COMMERCE antrol number

RANSMITTAL LETTE	ATTO ATE ODOCKET NUMBER 037003-0304261		
DESIGNATED/ELEC CONCERNING A FILI	U.S. APPRICATION TO THE TOTAL TO THE 1.6)		
ONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED	
PCT/US0318253	10 June 2003 (10.06.03)	10 June 2002 (10.06.02)	
IVENTION	NORTH AND THEM LICE AT DEVELO	NUMBER ADDITION	

INTERNATIONAL APPLICATION NO.	INIERNATIONAL FILING DATE	PRIORITI BATTE OCCUPANTO								
PCT/US0318253	10 June 2003 (10.06.03)	10 June 2002 (10.06.02)								
TITLE OF INVENTION GENES OVEREXPRESSED BY CAN	CER AND THEIR USE IN DEVELOPI	NG NOVEL THERAPEUTICS								
APPLICANT(S) FOR DO/EO/US Biogen I	dec, Inc., et al.									
Applicant herewith submits to the United Stat	es Designated/Etected Office (DO/EO/US) th	e following items and other information:								
1. This is a FIRST submission of items	concerning a filing under 35 U.S.C. 371.									
2. This is a SECOND or SUBSEQUENT submission of items concerning a filling under 35 U.S.C. 371.										
 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). 										
The US has been elected (Article 31).										
5. X A copy of the International Application	A copy of the International Application as filed (35 U.S.C. 371(c)(2))									
a. is attached hereto (require	a. Lis attached hereto (required only if not communicated by the International Bureau).									
b. In as been communicated to	b. I has been communicated by the International Bureau.									
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).										
 An English language translation of the a. is attached hereto. 	An English language translation of the International Application as med (00 0.0.0.0 17 (0/4))									
b. has been previously subm	itted under 35 U.S.C. 154(d)(4).	Elle I								
7. Amendments to the claims of the Int	7. X Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))									
a. X are attached hereto (requi	a. X are attached hereto (required only if not communicated by the International Bureau).									
	. 1971									
c. have not been made; how	ever, the time limit for making such amendm	ents has NOT expired.								
d. have not been made and		\$1.)								
8, 🔲 An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).										
9. An oath or declaration of the invento	•									
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
Items 11 to 20 below concern docume	nt(s) or information included:									
11. An Information Disclosure Statem										
12. An assignment document for reco	ording. A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is included.								
13. A preliminary amendment.	A preliminary amendment.									
14. X An Application Data Sheet under	An Application Data Sheet under 37 CFR 1.78.									
15. A substitute specification.		•								
1 · L1 ·	A power of attorney and/or change of address letter.									
17. A computer-readable form of the	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.									
l-uid	A second copy of the published international application under 35 U.S.C. 154(d)(4).									
19. A second copy of the English land	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).									
20. Other items or information:	,									

This collection of Information is required by 37 CFR 1.414 and 1.491-1.492. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) afth application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case, any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

703-905-2500

T-559 P.007/020 F-440

Alexandra De	And of 1986	on nemons are required to restit	U.S. Patent and Tonde	Office U.S. DETARTIVE	NT OF COMMERCE OMB control number			
U.S. APPLIC	Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of participation and Trade DITERNATIONAL APPLICATION NO. PCT/US03/18253		037003-0304261					
The following				CALCULATIONS PTO USE ONLY				
	FEE (37 CFR 1.492 (a) (
Moither international	preliminary examination	fee (37 CFR 1.482)						
nor international sea and International Sea	arch fee (37 CFR 1.445(8 sarch Report not prepare	d by the EPO or JPO · · · ·	\$1,100.00					
USPTO but Internal		area by the EPO of JPO						
but international sea	arch fee (37 CFR 1.445(a	CFR 1.482) not paid to U (2)) paid to USPTO · · ·	\$180.00					
but all claims did no	t satisfy provisions of PC		\$750.00					
International prelim and all claims satisf	inary examination fee (37 fied provisions of PCT Art	7 CFR 1.482) paid to USP dicle 33(1)-(4)	TO \$100.00					
	APPROPRIATE BAS	\$ 750.00	_					
Surcharge of \$130.0 from the earliest clair	ned priority date (37 CFF	or declaration later than 30 (1.492(e)).		\$ 0.00				
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$				
Total claims	52 - 20 =	32	x \$18.00	\$ 576.00				
Independent claims	2 -3 =	0	x \$88.00	\$ 0.00				
MULTIPLE DEPEND	ENT CLAIM(S) (if applica	able)	+ \$300.00	\$ 0.00				
	-	OTAL OF ABOVE CA		\$ 1,326.00				
Applicant claims are reduced by	s small entity status. See	\$ 0.00						
		\$ 1,326.00						
Processing fee of \$1 from the earliest claim	30.00 for furnishing the Emed priority date (37 CFF	\$ 0.00						
		\$ 1,326.00						
Fee for recording the	enclosed assignment (3 appropriate cover sheet (\$ 0.00						
		\$ 1,32 <u>6.00</u>						
		Amount to be refunded:	\$					
		Amount to be charged:	\$					
	the amount of the	to cover t	he above fees is encl	osed.				
a. A check in		000000		326.00 to cover t	he above feas.			
b. X Please charge my Deposit Account No. 033975 in the amount of \$ 1,326.00 to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 033975 A duplicate copy of this sheet is enclosed.								
		ard. WARNING: Informa	tion on this form may	become public. Credit o	a rd 10-2038.			
NOTE: Where an	annopriate time limit u	nder 37 CFR 1.495 has n	ot been met, a petiti					
(b)) must be filed	and granted to restore	the application to pendia	ng status.					
SEND ALL CORRESPONDENCE TO:								
Thomas A. Cawley, Jr., Ph.D.								
PILLSBURY W	INTHROP LLP	s A. Cawley, Jr., Ph.J	.					
P.O. Box 10500		3 M. Cawicy, Jr., Fil.						
McLean, VA 22102								
REGISTRATION NUMBER								

FORM PTO-1390 (REV 10-2004)